Super-Refractory Status Epilepticus
2
Pipeline Programs
1
Companies
3
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
0
0
1
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
1 companies ranked by most advanced pipeline stage
Supernus PharmaceuticalsMD - Rockville
3 programs1
1
SAGE-547Phase 31 trial
SAGE-547Phase 1/21 trial
SAGE-547N/A1 trial
Active Trials
NCT02433314No Longer Available
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Supernus PharmaceuticalsSAGE-547
Supernus PharmaceuticalsSAGE-547
Clinical Trials (3)
Total enrollment: 157 patients across 3 trials
A Study With SAGE-547 for Super-Refractory Status Epilepticus
Start: Jun 2015Est. completion: Aug 2017132 patients
Phase 3Completed
Study to Evaluate SAGE-547 Injection as Adjunctive Therapy for the Treatment of Super-Refractory Status Epilepticus
Start: Mar 2014Est. completion: May 201525 patients
Phase 1/2Completed
An Open Label, Expanded Access Protocol With SAGE-547 for Super-Refractory Status Epilepticus
N/ANo Longer Available
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 late-stage (Phase 3) programs, potential near-term approvals
1 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.